Search Results 1611-1620 of 21852 for Inhibition

1. Cholangiocarcinoma Clinical Trials - Mayo Clinic Research

   ... inhibitor treatment, 2) FGFR2 fusions who responded on prior FGFR inhibitor treatment and discontinued due to disease progression, 3) with other FGFR ...

2. Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Undergoing Surgery - Mayo Clinic

   Participants who regularly (>= 2 times per week) use drugs that alter the pH of the gastrointestinal (GI) tract, such as proton pump inhibitors (PPI) and ...

3. Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction - Mayo Clinic

   Chronic therapy with phosphodiesterase type-5 inhibitors (intermittent use of phosphodiesterase type-5 inhibitors for erectile dysfunction is allowable if ...

4. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

   Prior treatment with mTOR inhibitors or CDK 4/6 inhibitors in combination with endocrine therapy for treatment of metastatic disease. Prior treatment with ...

5. Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) - Mayo Clinic

   Received prior histone deacetylase (HDAC) inhibitor or deacetylase (DAC) inhibitor is not permitted such as Istodax (romidepsin/depsipetide) or valproic acid.

6. EDIT&RES Trial - Mayo Clinic

   Current use of monoamine oxidase inhibitors or use within 14 days following discontinuation of a monoamine oxidase inhibitors. Presence of mixed symptoms of ...

7. Olaparib (oral route) - Side effects & dosage - Mayo Clinic

   Olaparib is used as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of ...

8. Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases - Mayo Clinic

   Planned anti-cytotoxic therapies, other than tyrosine kinase inhibitors or single-agent monoclonal antibody, or FLT-3 inhibitors within 90 days of post ...

9. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) - Mayo Clinic

   ... inhibitors are permitted. NOTE: Warfarin may not be started while enrolled in ... inhibitor therapy is disallowed; suggested regimens to replace ...

10. Benign prostatic hyperplasia (BPH) - Diagnosis and treatment - Mayo Clinic

    5-alpha reductase inhibitors. ... Your health care provider might suggest that you take an alpha blocker and a 5-alpha reductase inhibitor at the same time if ...